FDA spurns Min­er­va’s schiz­o­phre­nia drug in RTF, send­ing share price in­to tail­spin

The writ­ing was on the wall.

The FDA spelled out its qualms with Min­er­va Neu­ro­sciences’ schiz­o­phre­nia drug can­di­date rolu­peri­done in 2020. Nev­er­the­less, the biotech pushed for­ward and had meet­ings with the reg­u­la­tor to at­tempt to as­suage con­cerns and get its drug to mar­ket.

So the biotech went ahead and, in Au­gust, asked the drug reg­u­la­tor to ap­prove the treat­ment for neg­a­tive symp­toms in peo­ple with schiz­o­phre­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER